News
Mixed
Volatility: 2/5
Trump’s Drug-Pricing Push to Cut Access Outside US, Study Finds
September 13, 2026
·
bloomberg
·
70% confidence
Summary
Trump drug-pricing push may lead pharma to cut access outside US, study finds.
AI Analysis
US drug price cuts pressure pharma revenues, but lower costs benefit insurers/PBMs. Sector-specific, limited broad S&P impact. Watch policy details.
Direction
Mixed
Volatility
2/5 - Low
AI Confidence
70%
Affected Stocks
PFE
MRK
LLY
ABBV
AMGN
CVS
UNH
CI
HUM
Likely Winners
CVS (CVS Health)
UNH (UnitedHealth)
CI (Cigna)
HUM (Humana)
Likely Losers
PFE (Pfizer)
MRK (Merck)
LLY (Eli Lilly)
ABBV (AbbVie)
AMGN (Amgen)
Suggested Action
Short PFE and MRK on US drug pricing pressure
Recommended Actions
- Short PFE and MRK on US drug pricing pressure
- Buy XLV puts to hedge pharma sector weakness
- Add UNH and CVS as beneficiaries of lower drug costs
- Monitor IBB and XBI for biotech volatility
- Watch for Trump administration drug pricing executive orders